The U.S. government has given $100 million to a drug company for the treatment of people with HIV who have been diagnosed with the virus, as it tries to reduce the number of new infections and keep the country’s HIV epidemic under control.
The funding for the Phase 2 drug, which will be tested on people in the United States, Canada and Mexico, was announced Tuesday by the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) on Twitter.HIV Treatment Centers for Excellence (HTCCE) will be created in Texas and New York, with additional centers in Chicago, Chicago, Detroit, Houston, Los Angeles, Milwaukee, Minneapolis, New York City, Oakland, Philadelphia and San Francisco.
The drug will be administered to people who have HIV who are receiving treatment at a facility or at a community health center.
The money will be used to expand the testing network for the drug, HHS said in a statement.
“I am the only one in the whole world who has a cure.
I have no doubts.
I’m the first one to have it,” said R. Kelly Rucker, founder and CEO of Rucker Therapeutics, a company that has developed a drug to treat HIV.”
The more I see and hear about people’s lives, the more I believe in it.
It’s a powerful medicine,” Rucker told Reuters Health.
The drug will have a half-life of 90 days, meaning that people with the drug’s effects are expected to have less of an effect on their bodies when they stop taking it.
Rucker said his company is currently testing the drug on HIV-positive people in Los Angeles.
“It’s going to be a year and a half before we get it in clinical trials,” Ruck said.HTC will use a combination of existing and new treatments to treat people with and without HIV, HHS added.
“The goal is to keep people on the drug.
There are no known side effects, and the drugs will not interfere with people’s daily activities,” HHS said.
The company will also use the drug to help those with HIV in the U.K., France and Israel, where people who were infected with HIV before starting treatment were allowed to continue using the drug without having to take a daily pill.
“If you are a person who is currently on a treatment regimen, we will continue that,” said HHS.
“This is an exciting opportunity to extend this approach to a broader, global community,” said Jason DeSantis, vice president for research at the National Institutes of Health (NIH).
“This funding will allow us to continue to advance our research in this field,” he said.
There are no new treatments for HIV in developed countries, and those currently being tested have been given limited results.
But in a trial last year in Australia, people on a new HIV drug were given up to 18 months of treatment, compared with about six months on a placebo.
The federal funding will be applied to the Phase 3 trial, which is set to start in 2021.